BioMarin Pharmaceutical Inc (BMRN) stock
BMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/3093% above fair value
$61.43+2.92 (+4.99%)
Close on Nov 18, 2026Market cap $11.89BP/E 161.7Yield –
BioMarin Pharmaceutical operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
BioMarin Pharmaceutical's operating income for the twelve months ending Jun 30, 2026 was $149.26M, down 80.8% year over year. For fiscal 2025 it was $409.48M, down 15.4% from the year before. The highest annual figure on record is $484.21M in fiscal 2024.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $409.48M | -15.4% |
| FY2024 | Dec 31, 2024 | $484.21M | +160.6% |
| FY2023 | Dec 31, 2023 | $185.77M | +15.4% |
| FY2022 | Dec 31, 2022 | $160.97M | – |
| FY2021 | Dec 31, 2021 | -$82.34M | – |
| FY2020 | Dec 31, 2020 | -$43.44M | – |
| FY2019 | Dec 31, 2019 | -$100.46M | – |
| FY2018 | Dec 31, 2018 | -$123.52M | – |
| FY2017 | Dec 31, 2017 | -$14.70M | – |
| FY2016 | Dec 31, 2016 | -$803.43M | – |
| FY2015 | Dec 31, 2015 | -$110.70M | – |
| FY2014 | Dec 31, 2014 | -$92.89M | – |
| FY2013 | Dec 31, 2013 | -$156.01M | – |
| FY2012 | Dec 31, 2012 | -$110.22M | – |
| FY2011 | Dec 31, 2011 | -$33.89M | -6329.8% |
| FY2010 | Dec 31, 2010 | $544.00K | -96.7% |
| FY2009 | Dec 31, 2009 | $16.43M | -58.7% |
| FY2008 | Dec 31, 2008 | $39.76M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $110.92M | -59.9% |
| Q1 FY2026 | Mar 31, 2026 | $129.64M | -42.1% |
| Q4 FY2025 | Dec 31, 2025 | -$44.61M | -127.6% |
| Q3 FY2025 | Sep 30, 2025 | -$46.69M | -141.0% |
| Q2 FY2025 | Jun 30, 2025 | $276.89M | +129.9% |
| Q1 FY2025 | Mar 31, 2025 | $223.89M | +153.1% |
| Q4 FY2024 | Dec 31, 2024 | $161.41M | +491.7% |
| Q3 FY2024 | Sep 30, 2024 | $113.89M | +273.1% |
| Q2 FY2024 | Jun 30, 2024 | $120.45M | +83.7% |
| Q1 FY2024 | Mar 31, 2024 | $88.46M | +41.8% |
| Q4 FY2023 | Dec 31, 2023 | $27.28M | – |
| Q3 FY2023 | Sep 30, 2023 | $30.53M | – |
| Q2 FY2023 | Jun 30, 2023 | $65.57M | +67.5% |
| Q1 FY2023 | Mar 31, 2023 | $62.40M | -54.6% |
| Q4 FY2022 | Dec 31, 2022 | -$13.09M | – |
| Q3 FY2022 | Sep 30, 2022 | -$2.42M | – |
| Q2 FY2022 | Jun 30, 2022 | $39.15M | +235.4% |
| Q1 FY2022 | Mar 31, 2022 | $137.33M | +447.4% |
| Q4 FY2021 | Dec 31, 2021 | -$65.88M | – |
| Q3 FY2021 | Sep 30, 2021 | -$53.22M | – |
| Q2 FY2021 | Jun 30, 2021 | $11.67M | – |
| Q1 FY2021 | Mar 31, 2021 | $25.09M | -76.1% |
| Q4 FY2020 | Dec 31, 2020 | -$51.52M | – |
| Q3 FY2020 | Sep 30, 2020 | -$55.94M | -1495.0% |
| Q2 FY2020 | Jun 30, 2020 | -$40.95M | – |
| Q1 FY2020 | Mar 31, 2020 | $104.96M | – |
| Q4 FY2019 | Dec 31, 2019 | -$9.16M | – |
| Q3 FY2019 | Sep 30, 2019 | $4.01M | – |
| Q2 FY2019 | Jun 30, 2019 | -$41.35M | – |
| Q1 FY2019 | Mar 31, 2019 | -$53.95M | – |
| Q4 FY2018 | Dec 31, 2018 | -$38.15M | -165.7% |
| Q3 FY2018 | Sep 30, 2018 | -$15.74M | – |
| Q2 FY2018 | Jun 30, 2018 | -$25.26M | – |
| Q1 FY2018 | Mar 31, 2018 | -$44.37M | – |
| Q4 FY2017 | Dec 31, 2017 | $58.05M | – |
| Q3 FY2017 | Sep 30, 2017 | -$13.73M | – |
| Q2 FY2017 | Jun 30, 2017 | -$38.81M | – |
| Q1 FY2017 | Mar 31, 2017 | -$20.21M | – |
| Q4 FY2016 | Dec 31, 2016 | -$89.62M | – |
| Q3 FY2016 | Sep 30, 2016 | -$60.09M | – |
See a number that looks wrong?